What is Atox Bio?
Atox Bio operates at the intersection of biotechnology and wellness, specializing in the development and distribution of high-quality human growth hormone (HGH) therapy products. The company distinguishes itself through a commitment to rigorous safety standards and transparent operational practices, catering to a diverse demographic that includes fitness enthusiasts, athletes, and individuals seeking optimized health outcomes. By leveraging verified injectable treatments and providing personalized support, Atox Bio has established a robust market presence, effectively bridging the gap between complex pharmaceutical innovation and consumer-facing wellness solutions.
How much funding has Atox Bio raised?
Atox Bio has raised a total of $56.3M across 3 funding rounds:
Series A
$3.3M
Series E
$23M
Series F
$30M
Series A (2011): $3.3M with participation from Esperante Ventures
Series E (2014): $23M led by SR One, Lundbeckfond Ventures, and OrbiMed
Series F (2017): $30M supported by Asahi Kasei Corporation, Adams Street Partners, Arix Bioscience, SR One, OrbiMed, and Integra Holdings
Key Investors in Atox Bio
OrbiMed
OrbiMed is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms with a hands-on approach to operational optimization.
SR One
SR One is a transatlantic biotechnology venture capital firm that invests in early and growth-stage life sciences companies, providing strategic support to translate innovative discoveries into new medicines.
Adams Street Partners
Adams Street Partners is a global private markets investment management firm founded in 1972, providing institutional-grade capital and strategic oversight to high-growth enterprises.
What's next for Atox Bio?
With the recent influx of capital, Atox Bio is well-positioned to accelerate its research and development pipeline, focusing on the refinement of its therapeutic offerings and the scaling of its distribution networks. The strategic involvement of high-caliber investors suggests a focus on long-term value creation, likely involving the optimization of clinical trial processes and the exploration of new therapeutic indications. As the company transitions into its next phase of growth, the emphasis will remain on maintaining regulatory compliance while expanding its footprint in the global biotech market, leveraging the operational expertise provided by its institutional partners to navigate the complexities of the healthcare sector.
See full Atox Bio company page
